Benzinga
Benzinga
Benzinga
domingo, septiembre 27

Edwards Lifesciences Corp

EWNYSE
Trade with Public
Trade with Public
$86.29
0.560.65%
al cierre: Sep 25, 5:00 PM EST
$85.50
-0.79-0.92%
After hour: Sep 25, 6:02 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Edwards Lifesciences Financials

Edwards Lifesciences (EW) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Vandana Singh

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Lifesciences, SAP in Focus (UPDATED)

U.S. stock futures were higher on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Thursday's lower close.
Rishabh Mishra

American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday

US stock futures mixed, focus on companies like American Express, Deckers, Verizon, Edwards Lifesciences, and HCA Healthcare for today's trading.
Avi Kapoor

PRO
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est

Edwards Lifesciences (NYSE:EW) is looking for Q3 Adj EPS of $0.71-$0.77 vs $0.74 analyst estimate. sees sales of $1.630 billion-$1.710 billion vs $1.689 billion analyst estimate.
Benzinga Newsdesk

PRO
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est

Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion
Benzinga Newsdesk

PRO
Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate

Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. This is a 16.42 percent increase over earnings of $0.67 per share from
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved